Article Menu
Need Help?
No Article Versions Notes Found
Cite
Llorca, P.-M.; Lançon, C.; Brignone, M.; Painchault, C.; Rive, B.; Toumi, M.; François, C. Can We Well Assess the Relative Efficacy and Tolerability of a New Drug Versus Others at the Time of Marketing Authorization Using Mixed Treatment Comparisons? A Detailed Illustration with Escitalopram. J. Mark. Access Health Policy 2015, 3, 26776. https://doi.org/10.3402/jmahp.v3.26776
Llorca P-M, Lançon C, Brignone M, Painchault C, Rive B, Toumi M, François C. Can We Well Assess the Relative Efficacy and Tolerability of a New Drug Versus Others at the Time of Marketing Authorization Using Mixed Treatment Comparisons? A Detailed Illustration with Escitalopram. Journal of Market Access & Health Policy. 2015; 3(1):26776. https://doi.org/10.3402/jmahp.v3.26776
Chicago/Turabian StyleLlorca, Pierre-Michel, Christophe Lançon, Mélanie Brignone, Caroline Painchault, Benoit Rive, Mondher Toumi, and Clément François. 2015. "Can We Well Assess the Relative Efficacy and Tolerability of a New Drug Versus Others at the Time of Marketing Authorization Using Mixed Treatment Comparisons? A Detailed Illustration with Escitalopram" Journal of Market Access & Health Policy 3, no. 1: 26776. https://doi.org/10.3402/jmahp.v3.26776
APA StyleLlorca, P.-M., Lançon, C., Brignone, M., Painchault, C., Rive, B., Toumi, M., & François, C. (2015). Can We Well Assess the Relative Efficacy and Tolerability of a New Drug Versus Others at the Time of Marketing Authorization Using Mixed Treatment Comparisons? A Detailed Illustration with Escitalopram. Journal of Market Access & Health Policy, 3(1), 26776. https://doi.org/10.3402/jmahp.v3.26776
